0.5555
22-11月-24 14:12:37
15 分の遅延
株式
-0.0145
-2.54%
本日の幅
0.5555 - 0.5996
ISIN
N/A
ソース
NASDAQ
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
08 11 2024 05:00:00 提供 Nasdaq GlobeNewswire
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
22 12 2023 06:00:00 提供 Nasdaq GlobeNewswire